Mereo BioPharma Group PLC ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.34
- Today's High:
- $1.41
- Open Price:
- $1.39
- 52W Low:
- $0.495
- 52W High:
- $1.77
- Prev. Close:
- $1.38
- Volume:
- 385160
Company Statistics
- Market Cap.:
- $179.98 million
- Book Value:
- 0.496
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $936000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.39%
- Return on Equity TTM:
- -45.63%
Company Profile
Mereo BioPharma Group PLC ADR had its IPO on 2019-04-24 under the ticker symbol MREO.
The company operates in the Healthcare sector and Biotechnology industry. Mereo BioPharma Group PLC ADR has a staff strength of 36 employees.
Stock update
Shares of Mereo BioPharma Group PLC ADR opened at $1.39 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.34 - $1.41, and closed at $1.4.
This is a +1.45% increase from the previous day's closing price.
A total volume of 385,160 shares were traded at the close of the day’s session.
In the last one week, shares of Mereo BioPharma Group PLC ADR have slipped by -2.78%.
Mereo BioPharma Group PLC ADR's Key Ratios
Mereo BioPharma Group PLC ADR has a market cap of $179.98 million, indicating a price to book ratio of 1.1697 and a price to sales ratio of 2.8264.
In the last 12-months Mereo BioPharma Group PLC ADR’s revenue was $0 with a gross profit of $936000 and an EBITDA of $-43425000. The EBITDA ratio measures Mereo BioPharma Group PLC ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mereo BioPharma Group PLC ADR’s operating margin was 0% while its return on assets stood at -25.39% with a return of equity of -45.63%.
In Q2, Mereo BioPharma Group PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Mereo BioPharma Group PLC ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.35 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mereo BioPharma Group PLC ADR’s profitability.
Mereo BioPharma Group PLC ADR stock is trading at a EV to sales ratio of 0.4058 and a EV to EBITDA ratio of -2.36. Its price to sales ratio in the trailing 12-months stood at 2.8264.
Mereo BioPharma Group PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $88.08 million
- Total Liabilities
- $24.68 million
- Operating Cash Flow
- $487000.00
- Capital Expenditure
- $5000
- Dividend Payout Ratio
- 0%
Mereo BioPharma Group PLC ADR ended 2024 with $88.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.08 million while shareholder equity stood at $61.87 million.
Mereo BioPharma Group PLC ADR ended 2024 with $0 in deferred long-term liabilities, $24.68 million in other current liabilities, 1875000.00 in common stock, $-331164000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $56.33 million and cash and short-term investments were $56.33 million. The company’s total short-term debt was $11,551,000 while long-term debt stood at $0.
Mereo BioPharma Group PLC ADR’s total current assets stands at $62.13 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.38 million compared to accounts payable of $2.89 million and inventory worth $0.
In 2024, Mereo BioPharma Group PLC ADR's operating cash flow was $487000.00 while its capital expenditure stood at $5000.
Comparatively, Mereo BioPharma Group PLC ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.4
- 52-Week High
- $1.77
- 52-Week Low
- $0.495
- Analyst Target Price
- $4.33
Mereo BioPharma Group PLC ADR stock is currently trading at $1.4 per share. It touched a 52-week high of $1.77 and a 52-week low of $1.77. Analysts tracking the stock have a 12-month average target price of $4.33.
Its 50-day moving average was $1.31 and 200-day moving average was $1.06 The short ratio stood at 5.2 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 5109.9% are held by institutions.
Frequently Asked Questions About Mereo BioPharma Group PLC ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.